Delivery Order SPE2DB20D2001-SPE2DB25FPLTQ

Award Date 1/2/25
Potential Completion Date 1/3/25
Potential Value $27K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $18,862.49 contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used for diabetes management. The contract has a period of performance through July 25, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $23,215.61, is for the delivery of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a pharmaceutical product used for diabetes management. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,163.67 firm fixed-price contract is for the delivery of OZEMPIC 1 mg/dose (4 mg/3 mL) 3 mL units. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,866.08, is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a specialty medication used for the treatment of diabetes. The contract has a firm fixed price pricing type and an ultimate completion date of January 7, 2025. This award is part of a larger Indefinite Delivery...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,751.66, is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used in the treatment of diabetes. The contract has a firm fixed price and an ultimate completion date of October 22, 2024. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,785.51 contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a specialty medication used for the treatment of diabetes. The contract has a firm fixed price pricing type and an ultimate completion date of December 18, 2024. This delivery order is likely part of a larger Indefinite...
This is a $1,961.94 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to the prime contractor AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a diabetes medication. The delivery order has an ultimate completion date of December 27, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $93,405.29 firm fixed price contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a medication used to treat diabetes. The contract has an ultimate completion date of November 21, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,879.98, is for the delivery of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a medication used for the treatment of diabetes. The contract has a firm fixed price and is a delivery order, with an ultimate completion date of December 30, 2024. The contract is not designated with a set-aside....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a medication used for diabetes management. The contract has a ceiling value of $1,479.32 and a completion date of October 29, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB20D2001
    Indefinite Delivery Contract
  • SPE2DB20D2001-SPE2DB25FPLTQ
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,490.31, is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used to treat diabetes. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition.

Generated 4/3/25, 10:55 AM